hotspot -WSS

hotspot

author：fashion 2025-09-02 11:34:39 - browse：4

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： FDA approves first new drug developed for postpartum depression

hotspot

WSS

Methadone treatment changes are coming. Do they go far enough?

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

FDA approves first new drug developed for postpartum depression

Stop the failed accountable care organization experiment

Biden administration plans revamp of organ transplant system

FDA approves first new drug developed for postpartum depression

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Duchenne breakthrough therapy leaves behind pioneering families

Reanimated hearts work just as well for transplants, study finds

Activists slam private health insurers over coverage restrictions

Can medical device makers keep up in the race to treat obesity?

Medicare proposal to cover medical devices draws a mixed reaction

Nurses recount patients attacks

How one medical school became remarkably diverse

Sea level rise could wash away turtle breeding grounds around the world, researchers say

explore

Living organ donors deserve priority status for transplants

Orchard's therapy for neuron disease in children wins FDA approval

Leading voice in opioid treatment defends methadone clinic system

Stop the failed accountable care organization experiment

Novo: Oral version of Ozempic leads to 15% weight loss

App could help diagnose ear infections more accurately — and at home

focus

hotspot

hotspot

leisure time